<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "JATS-journalpublishing1-4.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.4" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ojpsych</journal-id>
      <journal-title-group>
        <journal-title>Open Journal of Psychiatry</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2161-7333</issn>
      <issn pub-type="ppub">2161-7325</issn>
      <publisher>
        <publisher-name>Scientific Research Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.4236/ojpsych.2025.156035</article-id>
      <article-id pub-id-type="publisher-id">ojpsych-148045</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
        <subj-group>
          <subject>Biomedical</subject>
          <subject>Life Sciences</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Psychophysiological Reactions Related to Intoxication after Use of “Kadhafi” in a Case Received for Psychiatric Care in Abidjan</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gonce</surname>
            <given-names>Dion Aristide</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Amichia</surname>
            <given-names>Affibè Woria</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Ziketo</surname>
            <given-names>Bla Désirée Sandrine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sekongo</surname>
            <given-names>Yedjoutchari Diane</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>N’Guettia</surname>
            <given-names>Apolinaire</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahounou</surname>
            <given-names>Etobo Innocent</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Traoré</surname>
            <given-names>Brahim Samuel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiembre</surname>
            <given-names>Issaka</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koua</surname>
            <given-names>Asséman Médard</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yeo-Ténena</surname>
            <given-names>Yessonguilana Jean Marie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Addiction and Mental Health Departement of National Institute of Public Health (INSP), Abidjan, Côte d’Ivoire </aff>
      <aff id="aff2"><label>2</label> Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University of Abidjan, Abidjan, Côte d’Ivoire </aff>
      <aff id="aff3"><label>3</label> National Mental Health Programme of Côte d’Ivoire, Abidjan, Côte d’Ivoire </aff>
      <aff id="aff4"><label>4</label> Field Epidemiology Training Programme of Côte d’Ivoire, Abidjan, Côte d’Ivoire </aff>
      <author-notes>
        <fn fn-type="conflict" id="fn-conflict">
          <p>The authors declare no conflicts of interest.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>12</month>
        <year>2025</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2025</year>
      </pub-date>
      <volume>15</volume>
      <issue>06</issue>
      <fpage>449</fpage>
      <lpage>459</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>10</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>12</month>
          <year>2025</year>
        </date>
        <date date-type="published">
          <day>17</day>
          <month>12</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2025 by the authors and Scientific Research Publishing Inc.</copyright-statement>
        <copyright-year>2025</copyright-year>
        <license license-type="open-access">
          <license-p> This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> ). </license-p>
        </license>
      </permissions>
      <self-uri content-type="doi" xlink:href="https://doi.org/10.4236/ojpsych.2025.156035">https://doi.org/10.4236/ojpsych.2025.156035</self-uri>
      <abstract>
        <p><bold>Background</bold><bold>:</bold> The misuse of opiates is rapidly increasing, particularly among adolescents and young adults, with serious consequences for mental and physical health and social life. This descriptive case study addresses the physiological and psychological reactions associated with the use of Tramadol, in an illicit form locally known as “<italic>Kadhafi</italic>.” <bold>Methods</bold><bold>:</bold> The study was conducted at the Addiction and Mental Health Service (SAHM) in Abidjan from 1 to 27 July 2025. A case description was produced based on clinical observations and toxicological urine tests. <bold>Results</bold><bold>:</bold> The results reveal a 19-year-old student who presented with an increase in tongue volume (macroglossia) with protrusion, and glossoptosis associated with dizziness, headaches, insomnia, and anxiety, approximately one hour after taking a 250 mg tablet of illicit tramadol with alcohol. <bold>Conclusion</bold><bold>:</bold> This clinical case highlights acute opioid intoxication linked to the consumption of Tramadol in an illicit form, also known as “<italic>Kadh</italic><italic>afi</italic>.”</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated" xml:lang="en">
        <kwd>Adolescent</kwd>
        <kwd>Illegal Tramadol</kwd>
        <kwd>Poisoning</kwd>
        <kwd>Glossoptosis</kwd>
        <kwd>Macroglossia</kwd>
        <kwd>Ivory Coast</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>Opioid poisoning is now a global public health crisis. According to the World Health Organization (WHO), more than 58 million people use opioids, with a growing proportion using them for non-medical purposes. Nearly 110,000 overdose deaths were recorded in 2019, mainly linked to fentanyl and tramadol [<xref ref-type="bibr" rid="B1">1</xref>]. The chemical formula for tramadol is C<sub>16</sub>H<sub>25</sub>NO<sub>2</sub>, with a structure similar to that of morphine or codeine. Tramadol is a chiral molecule, with a racemic mixture whose enantiomers have a noradrenergic mechanism of action and opioid and serotonergic analgesic effects [<xref ref-type="bibr" rid="B2">2</xref>]. The effects of tramadol are stimulating and euphoric, which are often sought after by adolescents in their quest for improved performance at work, sexual performance, or relaxation [<xref ref-type="bibr" rid="B3">3</xref>]. As a result, the misuse of opiates is on the rise, particularly among adolescents and young adults, with serious consequences for mental and physical health and social life.</p>
      <p>In Africa, the phenomenon is reaching alarming proportions. Tramadol, a relatively accessible opioid drug, is trafficked and used extensively in several West African countries, including Nigeria, Ghana, Niger, Côte d’Ivoire, and Togo [<xref ref-type="bibr" rid="B4">4</xref>][<xref ref-type="bibr" rid="B5">5</xref>]. It is often used as a performance-enhancing drug or anxiolytic and consumed in tablet form or dissolved in homemade drinks. Its sale on the informal market encourages the proliferation of illicit forms, with high concentrations or combined with other psychoactive substances (PAS, any substances capable of altering brain function [<xref ref-type="bibr" rid="B6">6</xref>]), thereby increasing the risk of acute intoxication [<xref ref-type="bibr" rid="B7">7</xref>].</p>
      <p>In Côte d’Ivoire, although epidemiological data remain limited, there has been an increase in the consumption of tramadol among adolescents and young adults. The version known as “<italic>Kadhafi</italic>”, with a high dose of 225 mg or 250 mg, is commonly sold on the black market. Its use is frequently accompanied by psychiatric, neurological, and addictive complications, and, more rarely, by severe orofacial effects that are still poorly documented [<xref ref-type="bibr" rid="B7">7</xref>][<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>It was in this context that a case was reported on 24 June 2025 in Bingerville (population estimated at 204,656 in 2021) [<xref ref-type="bibr" rid="B9">9</xref>]. It is part of Greater Abidjan, the economic capital of Côte d’Ivoire. It was in this municipality that a 19-year-old boy presented with acute glossoptosis (an orofacial abnormality defined by a posterior fall of the tongue towards the oropharynx, which can lead to partial or complete obstruction of the upper airways) [<xref ref-type="bibr" rid="B10">10</xref>]-[<xref ref-type="bibr" rid="B12">12</xref>], macroglossia (abnormal enlargement of the tongue, which may be congenital) [<xref ref-type="bibr" rid="B13">13</xref>], with breathing difficulties, after consuming 250 mg of illicit Tramadol. It was these physiological and psychological reactions that sparked our interest in this study, the overall objective of which was to investigate opioid intoxication in this case.</p>
    </sec>
    <sec id="sec2">
      <title>2. Methods</title>
      <p>This was a descriptive clinical case study conducted from 1 to 25 July 2025 at the Addiction and Mental Health Department of the National Institute of Public Health/Abidjan, with an investigation phase carried out from 1 to 3 March 2025 in the commune of Bingerville (Côte d’Ivoire).</p>
      <p>The following was carried out to collect information:</p>
      <p>1) an individual interview, using a structured questionnaire with closed and open questions, the aim being to collect as much data as possible.</p>
      <p>2) direct observation of clinical manifestations.</p>
      <p>3) Access to medical information and reports from other professionals involved in the care of the patient or from the patient’s family and friends.</p>
      <p>4) Visits to health centres in the municipality of Bingerville and the surrounding area to search for cases.</p>
      <sec id="sec2dot1">
        <title>2.1. Variables of Interest</title>
        <p>1) Sociodemographic characteristics: age, gender, place of residence, educational level, occupation.</p>
        <p>2) Somatic and addiction-related clinical variables concerning the case: glossoptosis and/or macroglossia, stomatological malformations, perinatal complications, psychomotor development of the case, chronic diseases, medications currently being taken, convulsions of the case, head trauma, central nervous system infections, meningitis, epilepsy, neurological disorders of the tongue, asthma, use of herbal remedies, etc.</p>
        <p>3) Symptoms to observe: Presence of glossoptosis and/or macroglossia, duration, recurrence of the phenomenon, manifestations of glossoptosis and/or macroglossia after consumption of a product, associated symptoms, symptoms experienced before and after the phenomenon of glossoptosis and/or macroglossia, acute dystonia of the tongue, signs of abuse and dependence on psychoactive substances, side effects, behavioral disorders, breathing difficulties, convulsions, and withdrawal symptoms.</p>
        <p>4) Mental health variables: Psychological history: (suicidal thoughts, suicide attempts, self-harm, sexual abuse, maltreatment, conflict with parents, delinquency, history of psychiatric disorders). Symptoms to observe before the onset of the phenomenon<bold>:</bold>stress, frustration, emotional conflict, insomnia, sadness, hallucinations, delirium, and other symptoms. Psycho-emotional state at the time of the study: social withdrawal, anxiety, fear, sadness, insomnia, irritability, joy, incoherent speech, hallucinations, guilt, and perceived level of social support. </p>
        <p>5) Environmental variables: group of friends, family (conflict, family stress), precarious situations, etc.</p>
        <p>6) Representations of the phenomenon and reactions of witnesses (group of friends, parents).</p>
      </sec>
      <sec id="sec2dot2">
        <title>2.2. Laboratory Procedures</title>
        <p>A toxicological urine test (rapid test available in our context) was performed for the case. Chromatogram or spectrogram analyses were unavailable. Data from previous paraclinical investigations of the cases were collected.</p>
      </sec>
      <sec id="sec2dot3">
        <title>2.3. Data Management and Processing</title>
        <p>A simple description of the case was made based on clinical observations and paraclinical data.</p>
      </sec>
      <sec id="sec2dot4">
        <title>2.4. Ethical Considerations</title>
        <p>In order to carry out this research, it was essential to have an official framework that respected human rights, ethics, and professional conduct in research. An investigation authorisation from the Ministry of Health and Universal Health Coverage (MSHPCMU) via the National Mental Health Programme facilitated our access. Ethical aspects such as the right to anonymity and confidentiality of respondents were taken into consideration. The informed consent of respondents was mandatory prior to the investigation.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>3. Results (Observations)</title>
      <sec id="sec3dot1">
        <title>3.1. Psychobiography and Context of the Investigated Event</title>
        <p>This is DN, a 19-year-old male, single, residing in Bingerville, specifically in the SICOGI 1 neighbourhood, with a higher education level (1st year of university) (<bold>Table 1</bold>).</p>
        <p><bold>Table 1.</bold> Sociodemographic profile.</p>
        <table-wrap id="tbl1">
          <label>Table 1</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Sociodemographic</bold>
                  <bold>Profile</bold>
                </td>
                <td>
                  <bold>Description</bold>
                </td>
              </tr>
              <tr>
                <td>Gender</td>
                <td>Male</td>
              </tr>
              <tr>
                <td>Age</td>
                <td>19</td>
              </tr>
              <tr>
                <td>Single</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Level of education</td>
                <td>Higher</td>
              </tr>
              <tr>
                <td>Neighbourhood of residence</td>
                <td>Socogi 1, Bingerville</td>
              </tr>
              <tr>
                <td>Occupation</td>
                <td>Unemployed</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>He has no known or documented medical, surgical, or criminal history. However, he admits to having used cannabis and cigarettes in the past, from 2017 to 2021 (<bold>Table 2</bold>).</p>
        <p><bold>Table 2</bold><bold>.</bold> History.</p>
        <table-wrap id="tbl2">
          <label>Table 2</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>History</bold>
                </td>
                <td>
                  <bold>Description</bold>
                </td>
              </tr>
              <tr>
                <td>
                  <italic>
                    <bold>Medical and surgical</bold>
                  </italic>
                </td>
                <td>
                  <italic>
                    <bold>No particularities</bold>
                  </italic>
                </td>
              </tr>
              <tr>
                <td>Glossoptosis</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Macroglossia</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Meningitis</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Neurological disorders (languages)</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Stomatological disorders</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Head injury</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Other</td>
                <td>No</td>
              </tr>
              <tr>
                <td>
                  <italic>
                    <bold>Addiction specialists</bold>
                  </italic>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>
                  Illegal tramadol (
                  <italic>Kadhafi</italic>
                  )
                </td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Alcohol</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Tobacco</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Cannabis</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>
                  <italic>
                    <bold>Psychiatric</bold>
                  </italic>
                </td>
                <td>
                  <italic>
                    <bold>No particularities</bold>
                  </italic>
                </td>
              </tr>
              <tr>
                <td>
                  <italic>
                    <bold>Legal</bold>
                  </italic>
                </td>
                <td>
                  <italic>
                    <bold>No particularities</bold>
                  </italic>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The circumstances surrounding his birth were unremarkable, with good psychomotor development. After an average academic career, he voluntarily dropped out of his <sup>first</sup> year of university due to a lack of motivation. This led to a conflictual relationship with his biological parents, particularly his father. In terms of lifestyle, he did not take any medication but had been drinking alcohol occasionally since 2017 and had been taking an overdose of 250 mg of tramadol, known as the “<italic>Kadhafi</italic>” drug, since March 2025 in search of pleasure and sexual performance. Also frequented a group of friends who used psychoactive substances (PAS) and consumed them. “<italic>It was my friends who advised me</italic>,” he said. The first time he took the drug “<italic>Kadhafi</italic>”, often in combination with alcohol, there were no apparent problems. He took the drug twice a week, one tablet at a time (<bold>Table 3</bold>).</p>
        <p><bold>Table 3</bold><bold>.</bold> Psychobiography and lifestyle.</p>
        <table-wrap id="tbl3">
          <label>Table 3</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Psychobiography and</bold>
                  <bold>Lifestyle</bold>
                </td>
                <td>
                  <bold>Description</bold>
                </td>
              </tr>
              <tr>
                <td>Congenital malformations</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Psychomotor development</td>
                <td>Normal</td>
              </tr>
              <tr>
                <td>SPA user</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Consumption of decoction (traditional)</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Long-term treatment</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Comorbidities (chronic diseases)</td>
                <td>No</td>
              </tr>
              <tr>
                <td>
                  User of “
                  <italic>Kadhafi</italic>
                  ” since March 2025
                </td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>
                  Consumption of “
                  <italic>Kadhafi</italic>
                  ” on 24 June 2025 in combination with alcohol (wine), approximately 3 glasses.
                </td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Motivations related to sexual performance</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Motivations related to pleasure</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>
                  Clinical manifestations in the two friends who consumed the drug
                  <italic>Kadhafi</italic>
                </td>
                <td>No</td>
              </tr>
              <tr>
                <td>
                  Group of friends who used SPA (
                  <italic>Kadhafi</italic>
                  )
                </td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Glossoptosis in one friend in the past</td>
                <td>No</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>On 1 July 2025, he was seen for the first time in a psychiatric consultation, accompanied by his father and mother with a referral letter from the emergency department of Cocody University Hospital for intermittent protrusion of the tongue developing in the context of psychoactive opioid substance use, such as the drug “<italic>Kadhafi</italic>.”</p>
      </sec>
      <sec id="sec3dot2">
        <title>3.2. Interview, Clinical, and Paraclinical Data</title>
        <p>Before being admitted to the mental health department on 1 July 2025, the subject had consumed 250 mg of adulterated Tramadol in tablet form 10 minutes before drinking the wine on 24 June 2025, <italic>i.e.</italic>, seven days earlier. On that day, he was at the home of a friend’s parents; there were four of them, and only he and two friends consumed the drug “<italic>Kadhafi</italic>.” He was the only one who, about an hour after returning to his family home, presented with an increase in the volume of the tongue (macroglossia) with protrusion associated with dizziness and headaches (<bold>Table 4</bold>). His parents were alerted and took him to a private clinic, where he was kept under observation for four hours and received treatment consisting of benzodiazepine, with favourable results. Two days after this episode, our patient presented with glossoptosis at the back of the throat. The tongue was mobilised using the mother’s hair clip. The child was then admitted to the emergency department at Cocody University Hospital, where he was successfully treated <italic>with corticosteroids</italic>(normal tongue mobility restored) for two days (<bold>Table 4</bold>). Opiates were also found in his urine. Forty-eight hours later, he developed macroglossia with intermittent protraction of the tongue, which was stabilised in the emergency department of Cocody University Hospital. He also presented with insomnia, anxiety and the feeling of reliving previous symptoms. Physical examinations were normal, and given the psychological symptoms and opioid use, he was referred to the Addiction and Mental Health Department in Abidjan for treatment (<bold>Table 4</bold>). </p>
        <p>The somatic, addiction, and psychiatric examinations carried out on 1 July 2025 revealed the following symptoms:</p>
        <p>Macroglossia with intermittent protrusion (three times) of the tongue, breathing difficulties, and anxiety. No symptoms prior to consuming illicit tramadol and alcohol. No neurological tongue disorders, no stomatological disorders, no convulsions, no behavioural disorders, no symptoms of dependence, and no other psychiatric symptoms (<bold>Table 4</bold>).</p>
        <p>The two other friends who consumed the drug “<italic>Kadhafi</italic>” did not present with glossoptosis or macroglossia; they were known consumers of SPA, including “<italic>Kadhafi</italic>”. None of the patient’s friends had previously experienced glossoptosis or macroglossia after consuming the drug “<italic>Kadhafi</italic>”. However, they could not be interviewed during the investigation, as they refused to participate.</p>
      </sec>
      <sec id="sec3dot3">
        <title>3.3. Toxicological Examination of Urine</title>
        <p>The qualitative urine test was positive for opiates in the emergency room upon admission (Day 1).</p>
        <p>The follow-up test was positive for benzodiazepines and negative for opiates and other PAS during the addiction and mental health consultation (Day 7) (<bold>Table 4</bold>). Quantitative urine tests were not available, making it impossible to assess the dose-response relationship. Blood samples and toxicological analyses could not be performed in our setting.</p>
        <p><bold>Table 4</bold><bold>.</bold> Clinical profile.</p>
        <table-wrap id="tbl4">
          <label>Table 4</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Clinical and</bold>
                  <bold>Paraclinical Signs</bold>
                </td>
                <td>
                  <bold>Description</bold>
                </td>
              </tr>
              <tr>
                <td>
                  Insomnia before consuming “
                  <italic>Kadhafi</italic>
                  ”
                </td>
                <td>Present</td>
              </tr>
              <tr>
                <td>
                  <bold>Signs of abuse or intoxication after</bold>
                  <bold>consumption of the drug</bold>
                  <bold>“</bold>
                  <italic>
                    <bold>Kadhafi</bold>
                  </italic>
                  <bold>”</bold>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Duration of onset</td>
                <td>Approximately 1 hour after taking one 250 mg Tramadol tablet followed by 3 glasses of wine</td>
              </tr>
              <tr>
                <td>Dizziness</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Headaches</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Anxiety</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Glossoptosis</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Macroglossia</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Respiratory difficulties</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Angioedema</td>
                <td>Absent</td>
              </tr>
              <tr>
                <td>Signs of dependence</td>
                <td>Absent</td>
              </tr>
              <tr>
                <td>Withdrawal symptoms</td>
                <td>Absent</td>
              </tr>
              <tr>
                <td>
                  <bold>Psychiatric signs after consumption</bold>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Feeling of the tongue falling</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Fear</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>Guilt</td>
                <td>Present</td>
              </tr>
              <tr>
                <td>
                  <bold>Urine toxicology test</bold>
                </td>
                <td>
                </td>
              </tr>
              <tr>
                <td>Opiates (D1)</td>
                <td>Positive</td>
              </tr>
              <tr>
                <td>Benzodiazepine</td>
                <td>Positive</td>
              </tr>
              <tr>
                <td>Opiates and other psychoactive substances (D7)</td>
                <td>Negative</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="sec3dot4">
        <title>3.4. Treatment and Progression</title>
        <p>Treatment consisted of corticosteroids to manage inflammation and potential allergic reactions, antibiotics as prophylaxis against infection, muscle relaxants, and anticholinergics (trihexyphenidyl) to normalize tongue motility, benzodiazepines for anxiety, alimemazine to manage insomnia, and supportive psychotherapy. Following this, a positive outcome was observed, resulting in a clear regression of symptoms (<bold>Table 5</bold>).</p>
        <p><bold>Table 5</bold><bold>.</bold> Therapeutic and evolutionary profile.</p>
        <table-wrap id="tbl5">
          <label>Table 5</label>
          <table>
            <tbody>
              <tr>
                <td>
                  <bold>Therapeutic and evolutionary profile</bold>
                </td>
                <td>
                  <bold>Description</bold>
                </td>
              </tr>
              <tr>
                <td>Manual tongue-holding intervention</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Corticosteroid</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Benzodiazepine</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Antibiotic</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Muscle relaxant</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Anticholinergic</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Alimemazine</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Psychotherapy</td>
                <td>Yes</td>
              </tr>
              <tr>
                <td>Complication</td>
                <td>No</td>
              </tr>
              <tr>
                <td>Progress (2 weeks)</td>
                <td>Favourable</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>The case investigated concerns a 19-year-old male, single, with higher education, unemployed, who frequently consumes adulterated tramadol with friends, often in combination with alcohol. This profile matches that most frequently observed in studies on problematic tramadol use among young people. Adolescents and young adults are a population particularly vulnerable to opioid abuse, whether consumed alone or in combination with other substances [<xref ref-type="bibr" rid="B9">9</xref>][<xref ref-type="bibr" rid="B14">14</xref>][<xref ref-type="bibr" rid="B15">15</xref>]. According to the study by N’Djambara <italic>et al.</italic>, the age of first use is around 13 years [<xref ref-type="bibr" rid="B8">8</xref>]. Similarly, the work of Sarah Caupp <italic>et al.</italic> reported that 60.1% of opioid poisonings involved subjects aged 18 to 24, mostly male, often with co-use of benzodiazepines and alcohol [<xref ref-type="bibr" rid="B15">15</xref>]. Duke <italic>et al.</italic> highlighted the concept of co-ingestion among young tramadol users [<xref ref-type="bibr" rid="B16">16</xref>]. The main motivation in the case studied was the pursuit of sexual performance. N’Djambara <italic>et al.</italic> in Togo noted this motivation among tramadol users [<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>In this case, there was a history of addiction to psychoactive substances (<bold>Table 3</bold>). Psychomotor development was normal, and no congenital orofacial malformations such as Pierre Robin syndrome or other chronic comorbidities were reported. Acute toxicity appeared within 60 minutes of taking a 250 mg tablet of illicit tramadol and alcohol, with symptoms such as dizziness, headaches, and anxiety (<bold>Table 4</bold>). These clinical manifestations, consistent with tramadol intoxication, are corroborated by several studies [<xref ref-type="bibr" rid="B17">17</xref>]-[<xref ref-type="bibr" rid="B21">21</xref>].</p>
      <p>Although convulsions are frequently reported in tramadol abuse [<xref ref-type="bibr" rid="B17">17</xref>][<xref ref-type="bibr" rid="B22">22</xref>], no signs of convulsive seizures were observed here. However, unusual but clinically serious signs were noted: glossoptosis, macroglossia, glossitis, and breathing difficulties (<bold>Table 4</bold>). These signs are rare in the literature on opioids and seem to suggest an atypical presentation, but one potentially linked to the consumption of the drug “<italic>Kadhafi</italic>”, a substance identified locally as a diverted or illicit form of tramadol overdosed at 225 mg or 250 mg. In his study, Kouadio A reported the tongue falling back into the throat (glossoptosis) after the use of psychoactive substances consisting of overdosed “<italic>Kadhafi</italic>” tramadol sold on the black market [<xref ref-type="bibr" rid="B7">7</xref>]. In our study, glossoptosis and macroglossia were only present in the case investigated, with no other similar cases reported in the municipality of Bingerville.</p>
      <p>The two friends who consumed the drug “<italic>Kadhafi</italic>” did not present with glossoptosis, macroglossia, or other signs of acute intoxication. This could be explained by their acquired tolerance. This contrast illustrates both the inter-individual variability of pharmacological reactions, <italic>i.e.</italic>, individual metabolic differences, and possible variations in the composition of the tablets consumed.</p>
      <p>The toxicological examination of urine carried out on Day 1 confirmed the presence of opiates, supporting the hypothesis of acute tramadol intoxication. The test was negative on Day 7, in line with data in the literature indicating that tramadol is detectable for approximately three days after ingestion [<xref ref-type="bibr" rid="B17">17</xref>][<xref ref-type="bibr" rid="B23">23</xref>]. The presence of benzodiazepine in the urine on Day 7 was likely due to previous treatments (<bold>Table 5</bold>).</p>
      <p>Complete resolution of symptoms after two weeks, multidisciplinary therapeutic intervention including supportive psychotherapy, administration of corticosteroids to manage inflammation and potential allergic reactions, antibiotics as prophylaxis against infection, muscle relaxants, and anticholinergics (trihexyphenidyl) to normalise tongue motility, benzodiazepines for anxiety, alimemazine to manage insomnia, and manual intervention to prevent respiratory obstruction by the tongue, contributed to a favourable outcome (<bold>Table 5</bold>). These measures helped to limit serious complications, particularly the risk of asphyxia.</p>
      <p>The patient was part of a group of friends who used psychoactive substances, with a history of glossoptosis reported in one of them. Belonging to such a group, where psychoactive substance use is normalized, is a major risk factor for the initiation of risky behavior. Indeed, the influence of peer groups and friends increases, reaching a peak during adolescence [<xref ref-type="bibr" rid="B24">24</xref>].</p>
      <sec id="sec4dot1">
        <title>Limitations and Perspectives</title>
        <p>Our results cannot be generalized; this is a case study of a health event that has been very little documented, often due to limited biotechnical investigation resources in our context, hence the need for further in-depth pharmacological studies and quantitative studies.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <title>5. Conclusion</title>
      <p>This clinical case highlights acute opioid poisoning linked to the consumption of tramadol in an illicit form known locally as “<italic>Kadhafi</italic>” and co-ingested with alcohol. This case illustrates the diversity and severity of atypical clinical presentations associated with new forms of psychoactive substance use among adolescents. It highlights the need to raise awareness among young people, train health professionals to recognize the signs of poisoning, and establish a local epidemiological surveillance system to prevent or detect cases at an early stage.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">World Health Organisation (WHO) and United Nations: Office on Drugs and Crime (2021) World Drug Report 2021. United Nations Office on Drugs and Crime (UNODC). https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html</mixed-citation>
          <element-citation publication-type="report">
            <year>2021</year>
            <article-title>World Drug Report 2021</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Raffa, R.B., Friderichs, E., Reimann, W., Shank, R.P., Codd, E.E., Vaught, J.L., <italic>et al.</italic> (1993) Complementary and Synergistic Antinociceptive Interaction between the Enantiomers of Tramadol. <italic>The Journal of Pharmacology and Experimental Therapeutics</italic>, 267, 331-340. https://doi.org/10.1016/s0022-3565(25)39454-1 <pub-id pub-id-type="doi">10.1016/s0022-3565(25)39454-1</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0022-3565(25)39454-1">https://doi.org/10.1016/s0022-3565(25)39454-1</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Raffa, R.B.</string-name>
              <string-name>Friderichs, E.</string-name>
              <string-name>Reimann, W.</string-name>
              <string-name>Shank, R.P.</string-name>
              <string-name>Codd, E.E.</string-name>
              <string-name>Vaught, J.L.</string-name>
            </person-group>
            <year>1993</year>
            <article-title>Complementary and Synergistic Antinociceptive Interaction between the Enantiomers of Tramadol</article-title>
            <source>The Journal of Pharmacology and Experimental Therapeutics</source>
            <volume>3565</volume>
            <issue>25</issue>
            <pub-id pub-id-type="doi">10.1016/s0022-3565(25)39454-1</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Woromogo, S.H., Ngouyombo, A.D., Zulumur Mutwal, R.F. and Tebeu, P. (2024) 8-4—Factors Associated with Tramadol Misuse among Adolescents and Young Adults in Brazzaville in 2022. <italic>Journal of Epidemiology and Population Health</italic>, 72, Article ID: 202590. https://doi.org/10.1016/j.jeph.2024.202590 <pub-id pub-id-type="doi">10.1016/j.jeph.2024.202590</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jeph.2024.202590">https://doi.org/10.1016/j.jeph.2024.202590</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Woromogo, S.H.</string-name>
              <string-name>Ngouyombo, A.D.</string-name>
              <string-name>Mutwal, R.F.</string-name>
              <string-name>Tebeu, P.</string-name>
            </person-group>
            <year>2024</year>
            <article-title>8-4—Factors Associated with Tramadol Misuse among Adolescents and Young Adults in Brazzaville in 2022</article-title>
            <source>Journal of Epidemiology and Population Health</source>
            <volume>72</volume>
            <fpage>202590</fpage>
            <elocation-id>ID</elocation-id>
            <pub-id pub-id-type="doi">10.1016/j.jeph.2024.202590</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">International Narcotics Control Board (INCB) (2018) Special Report, Tramadol: Global Overview. https://www.incb.org/documents/Publications/AnnualReports/AR2018/Press_Kit/press_kit_French.pdf</mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Report, T</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Special Report, Tramadol: Global Overview</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Salm-Reifferscheidt, L. (2018) Tramadol: Africa’s Opioid Crisis. <italic>The Lancet</italic>, 391, 1982-1983. https://doi.org/10.1016/s0140-6736(18)31073-0 <pub-id pub-id-type="doi">10.1016/s0140-6736(18)31073-0</pub-id><pub-id pub-id-type="pmid">29864013</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/s0140-6736(18)31073-0">https://doi.org/10.1016/s0140-6736(18)31073-0</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Salm-Reifferscheidt, L.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Tramadol: Africa’s Opioid Crisis</article-title>
            <source>The Lancet</source>
            <volume>6736</volume>
            <issue>18</issue>
            <pub-id pub-id-type="doi">10.1016/s0140-6736(18)31073-0</pub-id>
            <pub-id pub-id-type="pmid">29864013</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Klein, A., Patwardhan, S. and Loglo, M.G.A. (2020) Divergences and Commonalities between the US Opioid Crisis and Prescription Medicine Mis/Use in West Africa. <italic>International Journal of Drug Policy</italic>, 76, Article ID: 102640. https://doi.org/10.1016/j.drugpo.2019.102640 <pub-id pub-id-type="doi">10.1016/j.drugpo.2019.102640</pub-id><pub-id pub-id-type="pmid">31931438</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.drugpo.2019.102640">https://doi.org/10.1016/j.drugpo.2019.102640</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Klein, A.</string-name>
              <string-name>Patwardhan, S.</string-name>
              <string-name>Loglo, M.G.A.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Divergences and Commonalities between the US Opioid Crisis and Prescription Medicine Mis/Use in West Africa</article-title>
            <source>International Journal of Drug Policy</source>
            <volume>76</volume>
            <fpage>102640</fpage>
            <elocation-id>ID</elocation-id>
            <pub-id pub-id-type="doi">10.1016/j.drugpo.2019.102640</pub-id>
            <pub-id pub-id-type="pmid">31931438</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Kouakou, A. (2023) Ivorian Youth, the Drug “Kadhafi”, and Sustainable Development. <italic>Graphies</italic><italic>francophones</italic>, No. 5, 307-320.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Kouakou, A.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Ivorian Youth, the Drug “Kadhafi”, and Sustainable Development</article-title>
            <source>Graphies francophones</source>
            <volume>307</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">N’Djambara, M., Epou, K. and Kpotchou, K. (2023) Words from the World of Psychotropic Drugs in Bè-Klikamé, Greater Lomé, Togo. <italic>Variations West African Journal of Social Sciences</italic>, 3, 9-33.</mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Djambara, M.</string-name>
              <string-name>Epou, K.</string-name>
              <string-name>Kpotchou, K.</string-name>
            </person-group>
            <year>2023</year>
            <article-title>Words from the World of Psychotropic Drugs in Bè-Klikamé, Greater Lomé, Togo</article-title>
            <source>Variations West African Journal of Social Sciences</source>
            <volume>3</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <citation-alternatives>
          <mixed-citation publication-type="web">National Institute of Statistics (INS) (2021) General Census of Population and Housing: Final Overall Results. https://www.ins.ci/RGPH2021/RESULTATS%20DEFINITIFSRP21.pdf</mixed-citation>
          <element-citation publication-type="web">
            <year>2021</year>
            <article-title>General Census of Population and Housing: Final Overall Results</article-title>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Huynh, C., Rochette, L., Pelletier, É. and Lesage, A. (2018) Defining Psychoactive Substance Use Disorders Based on Administrative Data. <italic>Mental Health in Quebec</italic>, 43, 39-64.</mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Huynh, C.</string-name>
              <string-name>Rochette, L.</string-name>
              <string-name>Lesage, A.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Defining Psychoactive Substance Use Disorders Based on Administrative Data</article-title>
            <source>Mental Health in Quebec</source>
            <volume>43</volume>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Zwahlen, R., Bütow, K., Morkel, J. and Naidoo, S. (2016) Pierre Robin Sequence: Subdivision, Data, Theories, and Treatment—Part 1: History, Subdivisions, and Data. <italic>Annals of Maxillofacial Surgery</italic>, 6, 31-34. https://doi.org/10.4103/2231-0746.186133 <pub-id pub-id-type="doi">10.4103/2231-0746.186133</pub-id><pub-id pub-id-type="pmid">27563603</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4103/2231-0746.186133">https://doi.org/10.4103/2231-0746.186133</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Zwahlen, R.</string-name>
              <string-name>Morkel, J.</string-name>
              <string-name>Naidoo, S.</string-name>
              <string-name>Subdivision, D</string-name>
              <string-name>History, S</string-name>
            </person-group>
            <year>2016</year>
            <article-title>Pierre Robin Sequence: Subdivision, Data, Theories, and Treatment—Part 1: History, Subdivisions, and Data</article-title>
            <source>Annals of Maxillofacial Surgery</source>
            <volume>6</volume>
            <pub-id pub-id-type="doi">10.4103/2231-0746.186133</pub-id>
            <pub-id pub-id-type="pmid">27563603</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Peter, H. and Penzel, T. (2025) Glossoptose. In: Peter, H., Penzel, T., Peter, J.H. and Peter, J.G., Eds., <italic>Enzyklopädie</italic><italic>der</italic><italic>Schlafmedizin</italic>, Springer, 431. https://doi.org/10.1007/978-3-662-65186-5_525 <pub-id pub-id-type="doi">10.1007/978-3-662-65186-5_525</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/978-3-662-65186-5_525">https://doi.org/10.1007/978-3-662-65186-5_525</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Peter, H.</string-name>
              <string-name>Penzel, T.</string-name>
              <string-name>Peter, H.</string-name>
              <string-name>Penzel, T.</string-name>
              <string-name>Peter, J.H.</string-name>
              <string-name>Peter, J.G.</string-name>
              <string-name>Schlafmedizin, S</string-name>
            </person-group>
            <year>2025</year>
            <article-title>Glossoptose</article-title>
            <source>In: Peter</source>
            <volume>431</volume>
            <pub-id pub-id-type="doi">10.1007/978-3-662-65186-5_525</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Ndiaye, O., Diouf, S., Fall, A., Moreira, C., Sylla, A., Guèye, M., <italic>et al.</italic> (2006) Macroglossia in Children: Description of Three Cases and Aetiological Diagnosis. <italic>Journal de</italic><italic>Pédiatrie</italic><italic>et de</italic><italic>Puériculture</italic>, 19, 207-210. https://doi.org/10.1016/j.jpp.2006.05.003 <pub-id pub-id-type="doi">10.1016/j.jpp.2006.05.003</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jpp.2006.05.003">https://doi.org/10.1016/j.jpp.2006.05.003</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Ndiaye, O.</string-name>
              <string-name>Diouf, S.</string-name>
              <string-name>Fall, A.</string-name>
              <string-name>Moreira, C.</string-name>
              <string-name>Sylla, A.</string-name>
            </person-group>
            <year>2006</year>
            <article-title>Macroglossia in Children: Description of Three Cases and Aetiological Diagnosis</article-title>
            <source>Journal de Pédiatrie et de Puériculture</source>
            <volume>19</volume>
            <pub-id pub-id-type="doi">10.1016/j.jpp.2006.05.003</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Spencer, M.R. and Weathers, S. (2020) Trends and Risk Factors of Adolescent Opioid Abuse/Misuse: Understanding the Opioid Epidemic among Adolescents. <italic>Interna</italic><italic>tional Journal of Adolescent Medicine and Health</italic>, 33, Article ID: 20180179. https://doi.org/10.1515/ijamh-2018-0179 <pub-id pub-id-type="doi">10.1515/ijamh-2018-0179</pub-id><pub-id pub-id-type="pmid">32396138</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1515/ijamh-2018-0179">https://doi.org/10.1515/ijamh-2018-0179</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Spencer, M.R.</string-name>
              <string-name>Weathers, S.</string-name>
            </person-group>
            <year>2020</year>
            <article-title>Trends and Risk Factors of Adolescent Opioid Abuse/Misuse: Understanding the Opioid Epidemic among Adolescents</article-title>
            <source>International Journal of Adolescent Medicine and Health</source>
            <volume>33</volume>
            <fpage>201801</fpage>
            <elocation-id>ID</elocation-id>
            <pub-id pub-id-type="doi">10.1515/ijamh-2018-0179</pub-id>
            <pub-id pub-id-type="pmid">32396138</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Caupp, S., Steffan, J., Shi, J., Wheeler, K.K., Spiller, H.A., Casavant, M.J., <italic>et al.</italic> (2018) Opioid Drug Poisonings in Ohio Adolescents and Young Adults, 2002-2014. <italic>Clinical Toxicology</italic>, 56, 765-772. https://doi.org/10.1080/15563650.2018.1424889 <pub-id pub-id-type="doi">10.1080/15563650.2018.1424889</pub-id><pub-id pub-id-type="pmid">29322813</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/15563650.2018.1424889">https://doi.org/10.1080/15563650.2018.1424889</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Caupp, S.</string-name>
              <string-name>Steffan, J.</string-name>
              <string-name>Shi, J.</string-name>
              <string-name>Wheeler, K.K.</string-name>
              <string-name>Spiller, H.A.</string-name>
              <string-name>Casavant, M.J.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Opioid Drug Poisonings in Ohio Adolescents and Young Adults, 2002-2014</article-title>
            <source>Clinical Toxicology</source>
            <volume>56</volume>
            <pub-id pub-id-type="doi">10.1080/15563650.2018.1424889</pub-id>
            <pub-id pub-id-type="pmid">29322813</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Duke, A.N., Bigelow, G.E., Lanier, R.K. and Strain, E.C. (2011) Discriminative Stimulus Effects of Tramadol in Humans. <italic>The Journal of Pharmacology and Experimental Therapeutics</italic>, 338, 255-262. https://doi.org/10.1124/jpet.111.181131 <pub-id pub-id-type="doi">10.1124/jpet.111.181131</pub-id><pub-id pub-id-type="pmid">21467190</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1124/jpet.111.181131">https://doi.org/10.1124/jpet.111.181131</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Duke, A.N.</string-name>
              <string-name>Bigelow, G.E.</string-name>
              <string-name>Lanier, R.K.</string-name>
              <string-name>Strain, E.C.</string-name>
            </person-group>
            <year>2011</year>
            <article-title>Discriminative Stimulus Effects of Tramadol in Humans</article-title>
            <source>The Journal of Pharmacology and Experimental Therapeutics</source>
            <volume>338</volume>
            <pub-id pub-id-type="doi">10.1124/jpet.111.181131</pub-id>
            <pub-id pub-id-type="pmid">21467190</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <citation-alternatives>
          <mixed-citation publication-type="thesis">Picard, H. (2003) Acute Tramadol Hydrochloride Poisoning: Four Case Reports. Master’s Thesis, Université Henri Poincaré. https://hal.univ-lorraine.fr/hal-01733436</mixed-citation>
          <element-citation publication-type="thesis">
            <person-group person-group-type="author">
              <string-name>Picard, H.</string-name>
              <string-name>Thesis, U</string-name>
            </person-group>
            <year>2003</year>
            <article-title>Acute Tramadol Hydrochloride Poisoning: Four Case Reports</article-title>
            <source>Master’s Thesis</source>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Moulis, F., Rousseau, V., Abadie, D., Masmoudi, K., Micallef, J., Vigier, C., <italic>et al.</italic> (2017) Serious Adverse Drug Reactions with Tramadol Reported to the French Pharmacovigilance Database between 2011 and 2015. <italic>Therapies</italic>, 72, 615-624. https://doi.org/10.1016/j.therap.2017.03.004 <pub-id pub-id-type="doi">10.1016/j.therap.2017.03.004</pub-id><pub-id pub-id-type="pmid">28755832</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.therap.2017.03.004">https://doi.org/10.1016/j.therap.2017.03.004</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Moulis, F.</string-name>
              <string-name>Rousseau, V.</string-name>
              <string-name>Abadie, D.</string-name>
              <string-name>Masmoudi, K.</string-name>
              <string-name>Micallef, J.</string-name>
              <string-name>Vigier, C.</string-name>
            </person-group>
            <year>2017</year>
            <article-title>Serious Adverse Drug Reactions with Tramadol Reported to the French Pharmacovigilance Database between 2011 and 2015</article-title>
            <source>Therapies</source>
            <volume>72</volume>
            <pub-id pub-id-type="doi">10.1016/j.therap.2017.03.004</pub-id>
            <pub-id pub-id-type="pmid">28755832</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Hassamal, S., Miotto, K., Dale, W. and Danovitch, I. (2018) Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. <italic>The American Journal of Medicine</italic>, 131, 1382.e1-1382.e6. https://doi.org/10.1016/j.amjmed.2018.04.025 <pub-id pub-id-type="doi">10.1016/j.amjmed.2018.04.025</pub-id><pub-id pub-id-type="pmid">29752906</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjmed.2018.04.025">https://doi.org/10.1016/j.amjmed.2018.04.025</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Hassamal, S.</string-name>
              <string-name>Miotto, K.</string-name>
              <string-name>Dale, W.</string-name>
              <string-name>Danovitch, I.</string-name>
            </person-group>
            <year>2018</year>
            <article-title>Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures</article-title>
            <source>The American Journal of Medicine</source>
            <volume>131</volume>
            <pub-id pub-id-type="doi">10.1016/j.amjmed.2018.04.025</pub-id>
            <pub-id pub-id-type="pmid">29752906</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <citation-alternatives>
          <mixed-citation publication-type="journal">Khosrojerdi, H., Alipour Talesh, G., Danaei, G.H., Shokooh Saremi, S., Adab, A. and Afshari, R. (2015) Tramadol Half Life Is Dose Dependent in Overdose. <italic>DARU Journal of Pharmaceutical Sciences</italic>, 23, Article No. 22. https://doi.org/10.1186/s40199-015-0104-y <pub-id pub-id-type="doi">10.1186/s40199-015-0104-y</pub-id><pub-id pub-id-type="pmid">25888861</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40199-015-0104-y">https://doi.org/10.1186/s40199-015-0104-y</ext-link></mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <string-name>Khosrojerdi, H.</string-name>
              <string-name>Talesh, G.</string-name>
              <string-name>Danaei, G.H.</string-name>
              <string-name>Saremi, S.</string-name>
              <string-name>Adab, A.</string-name>
              <string-name>Afshari, R.</string-name>
            </person-group>
            <year>2015</year>
            <article-title>Tramadol Half Life Is Dose Dependent in Overdose</article-title>
            <source>DARU Journal of Pharmaceutical Sciences</source>
            <volume>23</volume>
            <elocation-id>No</elocation-id>
            <pub-id pub-id-type="doi">10.1186/s40199-015-0104-y</pub-id>
            <pub-id pub-id-type="pmid">25888861</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Cossmann, M., Kohnen, C., Langford, R. and McCartney, C. (1997) Tolerance and Safety of Tramadol Use. Results of International Studies and Data from Drug Surveillance. <italic>Drugs</italic>, 53, 50-62. https://doi.org/10.2165/00003495-199700532-00010 <pub-id pub-id-type="doi">10.2165/00003495-199700532-00010</pub-id><pub-id pub-id-type="pmid">9190325</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00003495-199700532-00010">https://doi.org/10.2165/00003495-199700532-00010</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Cossmann, M.</string-name>
              <string-name>Kohnen, C.</string-name>
              <string-name>Langford, R.</string-name>
              <string-name>McCartney, C.</string-name>
            </person-group>
            <year>1997</year>
            <article-title>Tolerance and Safety of Tramadol Use</article-title>
            <source>Results of International Studies and Data from Drug Surveillance. Drugs</source>
            <volume>53</volume>
            <pub-id pub-id-type="doi">10.2165/00003495-199700532-00010</pub-id>
            <pub-id pub-id-type="pmid">9190325</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <citation-alternatives>
          <mixed-citation publication-type="report">Abadie, D., Durrieu, G., Roussin, A. and Montastruc, J. (2013) Serious Adverse Effects of Tramadol: 2010-2011 Pharmacovigilance Report in France. <italic>Therapies</italic>, 68, 77-84. https://doi.org/10.2515/therapie/2013021 <pub-id pub-id-type="doi">10.2515/therapie/2013021</pub-id><pub-id pub-id-type="pmid">23773348</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2515/therapie/2013021">https://doi.org/10.2515/therapie/2013021</ext-link></mixed-citation>
          <element-citation publication-type="report">
            <person-group person-group-type="author">
              <string-name>Abadie, D.</string-name>
              <string-name>Durrieu, G.</string-name>
              <string-name>Roussin, A.</string-name>
              <string-name>Montastruc, J.</string-name>
            </person-group>
            <year>2013</year>
            <article-title>Serious Adverse Effects of Tramadol: 2010-2011 Pharmacovigilance Report in France</article-title>
            <source>Therapies</source>
            <volume>68</volume>
            <fpage>2010</fpage>
            <lpage>2011</lpage>
            <pub-id pub-id-type="doi">10.2515/therapie/2013021</pub-id>
            <pub-id pub-id-type="pmid">23773348</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Dayer, P., Desmeules, J. and Collart, L. (1997) Pharmacology of Tramadol. <italic>Drugs</italic>, 53, 18-24. https://doi.org/10.2165/00003495-199700532-00006 <pub-id pub-id-type="doi">10.2165/00003495-199700532-00006</pub-id><pub-id pub-id-type="pmid">9190321</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/00003495-199700532-00006">https://doi.org/10.2165/00003495-199700532-00006</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Dayer, P.</string-name>
              <string-name>Desmeules, J.</string-name>
              <string-name>Collart, L.</string-name>
            </person-group>
            <year>1997</year>
            <article-title>Pharmacology of Tramadol</article-title>
            <source>Drugs</source>
            <volume>53</volume>
            <pub-id pub-id-type="doi">10.2165/00003495-199700532-00006</pub-id>
            <pub-id pub-id-type="pmid">9190321</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <citation-alternatives>
          <mixed-citation publication-type="other">Bohrn, K. and Fenk, R. (2003) The Influence of Peer Groups on Drug Use. <italic>Psyc</italic><italic>hotropes</italic>, 9, 195-202. https://doi.org/10.3917/psyt.093.0195 <pub-id pub-id-type="doi">10.3917/psyt.093.0195</pub-id><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3917/psyt.093.0195">https://doi.org/10.3917/psyt.093.0195</ext-link></mixed-citation>
          <element-citation publication-type="other">
            <person-group person-group-type="author">
              <string-name>Bohrn, K.</string-name>
              <string-name>Fenk, R.</string-name>
            </person-group>
            <year>2003</year>
            <article-title>The Influence of Peer Groups on Drug Use</article-title>
            <source>Psychotropes</source>
            <volume>9</volume>
            <pub-id pub-id-type="doi">10.3917/psyt.093.0195</pub-id>
          </element-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>